We investigated the effects of novel antagonists of growth hormone releasing hormone (GHRH)-MIA602 and MIA690-on three human small cell lung cancer (SCLC) lines (H446, DMS53 and H69) and two non-SCLC (NSCLC) lines (HCC827 and H460). In vitro exposure of cancer cells to these GHRH antagonists significantly inhibited cell viability, increased cell apoptosis, decrease cellular levels of cAMP and reduced cell migration. In vivo, the antagonists strongly inhibited tumor growth in xenografted nude mice models. Subcutaneous administration of MIA602 at the dose of 5 lg/day for 4-8 weeks reduced the growth of HCC827, H460 and H446 tumors by 69.9%, 68.3% and 53.4%, respectively, while MIA690 caused a reduction of 76.8%, 58.3% and 54.9%, respectively. Western blot and qRT-PCR analyses demonstrated a downregulation of expression of the pituitary-type GHRH-R and its splice-variant, cyclinD1/2, cyclin-dependent kinase4/6, p21-activated kinase-1, phosphorylation of activator of transcription 3 and cAMP response element binding protein; and an upregulation of expression of E-cadherin, b-catenin and P27 kip1 in cancer cells and in xenografted tumor tissues. The study demonstrates the involvement of GHRH antagonists in multiple signaling pathways in lung cancers. Our findings suggest the merit of further investigation with these GHRH antagonists on the management of both SCLC and NSCLC.
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Lung cancer is one of the most common cancers and the leading cause of cancer-related death in the world. 1 Every year, new cases of lung cancer total >1.8 million worldwide with a high death rate. 1 Despite major progress in surgery, chemotherapy, radiotherapy and biological targeted therapies, 2,3 the overall five-year survival rate for lung cancer is still only 17.7% in USA. 4 New and more efficacious strategies of treatment are needed.
Growth hormone-releasing hormone (GHRH) is a hypothalamic peptide neuro-hormone that regulates the release of growth hormone (GH) from the pituitary GHRH also exerts direct stimulatory effects on various extrapituitary cells or tissues through the GHRH receptors (GHRH-Rs). In tumors, GHRH acts as an autocrine/paracrine growth factor and stimulates growth of various cancers. [5] [6] [7] In the past two decades, many antagonists of GHRH have been synthesized, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] which show potent inhibitory effects on growth of various tumors, including small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). [17] [18] [19] [20] [21] [22] [23] [24] In contrast to a weak expression of GHRH receptors in normal human lung tissues, 25 the levels of pituitary-type of GHRH receptor (pGHRH-R) and its splice variant type 1 receptor (SV1) are dramatically increased in human lung cancer tissue and in established lung cancer cell lines. 25 Several signaling pathways such as Raf/Mek/ERK1/2, PI3K/ AKT and AMPK metabolic pathway in NSCLCs 22, 23, 26 ; EGF/ HER and PKC pathways in SCLCs 21, 27 appear to be involved in the inhibitory effects of GHRH antagonists on lung tumors.
Based on the promising antitumor properties of GHRH antagonists in lung cancers, additional GHRH antagonists with improved bioavailability, reduced biodegradation and increased affinity to the receptors have been designed and synthesized. 16 In this study we evaluated the effects of two GHRH antagonists of MIAMI series, MIA602 and MIA690, on cell proliferation of lung cancers in vitro, and on tumor growth in xenografted animal models of SCLC and NSCLC. We also evaluated the effects of these antagonists on the expression of GHRH receptors and their influence in cell signaling pathways, which have not yet been investigated in the lung cancers, such as cyclic AMP/cyclic AMP response element binding protein (cAMP/CREB), p21-activated kinase-1 (PAK-1) and signal transducer and activator of transcription 3 (STAT3) pathways, and effector proteins in G1/S transition check-point in cell cycle. Our findings suggest that GHRH-R is a promising marker and therapeutic target for management of lung cancer.
Materials and Methods

Peptides and chemicals
GHRH antagonists MIA602 and MIA690 were synthesized in our laboratory by solid phase methods and purified by HPLC. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] The peptides (5 mM) were dissolved in DMSO, and further diluted in cell culture media to the concentration indicated. The final concentration of DMSO in the culture medium was 0.1% (v/v).
Cell culture
Human lung cancer cell lines H446, H69, HCC827, H460 and DMS53 were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and cultured at 378C in a humidified 95% air/5% CO 2 atmosphere in the medium recommended by ATCC.
Human lung tissue
Human lung tissue from a healthy donor was obtained from the Department of Medicine at University of Miami School of Medicine. The local Institutional Review Board for use of human subjects at University of Miami School of Medicine, and the Research and Development Committee of the Veterans Affairs Medical Center in Miami approved the protocol for collection and use of human specimens and authorized the study.
In vitro cell viability and apoptosis assays
Cell viability was analyzed as described. 28 
Protein isolation and Western blot assay
Briefly, the lung cancer cells were cultured as described above, treated with 5 lM GHRH antagonists for 48 or 72 hr, and cells were washed with PBS twice. Cellular protein was isolated using Cell Lysis Reagent (Cell Signaling, USA). The tumor tissues were chopped into small pieces, sonicated in lysis reagent at 40% amplitude for 3 3 5 sec on ice. Western blots were performed as previously described. 28 Quantification of density of signals was performed using (Biorad Quantityone Software). The intensity of specific proteins was normalized to that of b-actin. The antibodies to GHRH receptor (ab28692) and CDK6 (ab194871) were from Abcam
What's new? Growth hormone releasing hormone (GHRH) antagonists have shown promising antitumor properties in lung cancers. Here, the authors found that new GHRH antagonists MIA602 and MIA690 inhibit the growth of human lung cancers including small cell lung cancer (SCLC) and non-SCLC in vitro and in vivo, and reduce expression of GHRH receptors in lung cancer cells and tumors. This study also reveals the modulating effect of GHRH antagonists on the expression of key proteins in the cell cycle G1/S checkpoint and on the cAMP/CREB and PAK-STAT3 signaling pathways. GHRH antagonists offer a new therapeutic approach to the management of lung cancer.
Biotechnology (Cambridge, United Kingdom). The antibodies to CREB (#9197S), p-CREB (#9198S), STAT3 (#4904S), p-STAT3 (#9145S), cyclin D1 (#2922S), cyclin D2 (#3741S), PAK1 (#2602S), CDK4 (#2906), p27 kip1 (#3686S), and b actin (#4967S) were from Cell Signaling Technology (Danvers, US). The secondary antibodies were from Santa Cruz Biotechnology (Dallas, US).
Cell scratch assay
Lung cancer cells were grown in full medium to an 80-90% confluent monolayer. Medium containing 2% FBS with or without 2 lM GHRH antagonists was applied. A scratch was created manually, and the cells were further incubated at 378C. The gap distance was measured at 0, 12, 24 and 36 hr under microscope. The data represent the average distance from 100 locations along the gap at each time point.
Measurement of cellular cAMP
Lung cancer cells in culture were starved in media containing 0.5% FBS for 24 hr, and treated with media containing 0.5% FBS, 100 lM 3-isobutyl-1-methylxanthine (IBM-X, Sigma) and 2 lM of GHRH antagonists (or vehicle solutions) for 1 hr. Cellular cAMP levels were measured by cAMP EIA kit from Cayman Chemicals (Ann Arbor, US) following manufacturer's instructions.
Quantitative real-time PCR (qRT-PCR) analysis
qRT-PCR analyses was performed as previously described 28 using the following thermal settings: denaturation at 958C for 3 min, followed by 40 cycles of 958C, 30 sec, and 628C, 1 min. All reactions were performed in triplicate. Gene expression analysis was conducted using CFX manager software (BioRad). The primers used were as follows:
Human E-cadherin (Forward:
Statistical analysis
One-way ANOVA followed by Bonferroni comparison was performed. Data are expressed as mean 6 SEM. To determine statistical significance between animal groups, two-tailed Student's t test was conducted. Differences were considered significant when p < 0.05.
Results
Expression of GHRH receptors in lung cancer cells
Five lung cancer cell lines were analyzed, including HCC827 adenocarcinoma lung cancer cell line of non-small-cancer lung cancer (NSCLC), H460 large-cell lung cancer (LCLC) cell line of NSCLC and three small cancer lung cancer (SCLC) cell lines H446, H69 and DMS53. As shown in Figure 1a , both pituitary-type GHRH receptor (pGHRH-R) and its splice variant 1 (SV1) were expressed in all five lung cancer cell lines as shown by Western blot analyses. The levels of pGHRHR were similar in these five cell lines, and slightly weaker in normal lung tissues. SV1 type of receptor was expressed in all five lung cancer cell lines, while it was hardly detectable in normal lung tissue (Fig. 1a) . The GHRH Immunocytochemistry analyses revealed that GHRH receptor(s) were mainly located on cell membrane and cytoplasm of the cancer cells (Fig. 1b) .
The GHRH antagonists MIA602 and MIA690 inhibit cell viability and promote apoptosis of lung cancer cells
The effects of GHRH antagonists on the growth of lung cancer cells in vitro are shown in Figure 1c . Fig. 1c ). Correspondingly, cell apoptosis was dramatically increased when the same treatments were applied (Fig. 1c) and, different cells responded to GHRH antagonists to a different extent.
Treatment with GHRH antagonists MIA602 and MIA690 inhibits the growth of lung tumors in nude mice
To evaluate the efficacy of therapy in a clinically relevant system, the xenograft models were used to examine the effect of GHRH antagonists. Three cell lines HCC827, H460 and H446 were selected for the study. Mice bearing HCC827 and H446 tumors were treated s.c. with GHRH antagonists MIA602, MIA690 or the vehicle for 8 weeks, while the animals bearing H460 tumors were similarly treated for 4 weeks. Growth of all three tumors, followed by measuring tumor volume in the treated animals, was significantly suppressed. In mice xenografted with HCC827, H460 and H446, tumor growth was suppressed by 69.9%, 68.3% and 53.4%, respectively, after treatment with MIA602; and by 76.8%, 58.3% and 54.9%, respectively, following therapy with MIA690 (Fig. 2 ). There were no significant differences in body weights among the treatment groups (data not shown).
Downregulation of GHRH receptors after treatment with antagonists MIA602 and MIA690
Western blot analyses demonstrated that the expression of pGHRH-R and SV1 in the HCC827, H460 and H446 lung cancer lines was significantly decreased upon in vitro treatment with 5 lM MIA602 or MIA690 for 72 hr ( Fig. 3a and Supporting Information, Table S1 ). The reduction of pGHRH-R in HCC827, H460 and H446 cells after exposure to MIA602 in vitro for 72 hr was 18%, 28% and 52%, respectively; and after MIA690 treatment, 26%, 57% and 38%, respectively (p < 0.05). The decrease of SV1 in HCC827, H460 and H446 lines was 15%, 41% and 75%, respectively, after MIA602 treatment, and 16%, 70% and 81%, respectively, after exposure to MIA690 (p < 0.05). Administration of GHRH antagonists for 4-8 weeks to nude mice bearing the tumors led to a similar significant downregulation of receptors of GHRH. In the xenografted HCC827, H460 and H446 tumors, the reduction of pGHRH-R was 38%, 19% and 20%, respectively, after MIA602 treatment, and 39%, 39% and 30%, respectively, after therapy with MIA690. In the same tumors, the reduction of SV1 was 25%, 39% and 30%, respectively, after MIA602 treatment, and 41%, 32% and 30%, respectively, after MIA690 therapy ( Fig. 3b and Supporting Information, Table S1 ).
Treatment with GHRH antagonists inhibits the migration of lung cancer cells in culture
The effects of GHRH antagonists on the malignancy of cancer cells were analyzed in HCC827, H460 and H446 cells in vitro using cell migration assay. As shown in Figure 4a , treatment of these three cancer cells with 2lM MIA602 for 24 hr significantly reduced cell migration activity in HCC827, H460 and H446 cells by 51.5%, 61.5% and 65.0%, respectively. A similar treatment with MIA690 reduced cell migration by 53.0%, 61.5% and 72.5%, respectively (Fig. 4a) . qRT-PCR showed that the treatment with MIA602 and MIA690 stimulated the expression of mRNA for E-cadherin and b-catenin ( Fig. 4b and c and Supporting Information, Table S2 ). Western blot analyses revealed that the expression of E-cadherin and b-catenin was also significantly upregulated after treatment of cells with MIA602 or MIA690 for 48 and 72 hr (Fig.  4d) . As expected, the expression of E-cadherin and b-catenin proteins in the xenografted tumors from animals treated in vivo with MIA602 and MIA690 was similarly upregulated, although the changes of E-cadherin levels following therapy with MIA690 were only minor ( Fig. 4e and Supporting Information, Table S1 ).
GHRH antagonists inhibit the growth and progression of lung cancer by modulating the expression of effector proteins in cell cycle G1/S transition check point in lung cancers
We also investigated the effector proteins involved in G1/S transition cell cycle control. Western blot analyses revealed that the expression of cyclins (cyclin D1, cyclin D2) and cyclin-dependent kinases (CDKs, (CDK4 and CDK6)), was downregulated in the lung cancer cells treated in vitro with 5 lM MIA602 and MIA690 for 72 hr, and in the tumor tissues upon treatment with GHRH antagonists in vivo ( Fig. 5 and Supporting Information, Table S1 ). Interestingly, the expression of p27 kip1 , the conditional inhibitor for CDK4/6, was upregulated by the same treatment ( Fig. 5 and Supporting Information, Table S1 ). Both antagonists affected the expression of these proteins; however, MIA602 was more potent than MIA690 in general. Furthermore, flow cytometry analyses of cell cycle indicated that treatment of lung cancer cells with GHRH antagonists resulted in decreasing of cell population in S and G2 phases (Supporting Information, Figs. S1-S3).
GHRH antagonists downregulate PAK1-STAT3 and cAMP/ CREB signaling pathways in lung cancers
We also evaluated the expression of effector proteins in PAK1-STAT3 pathway following exposure in vitro to 5 lM MIA602 and MIA690 for 72 hr. Western blot analyses revealed that, the levels of activated STAT3 (pSTAT3/ STAT3) and PAK1 were significantly downregulated in all three lung cancers ( Fig. 6a and Supporting Information, Table S1 ). Similar results were obtained for the specimens of tumor tissues, except there was no obvious inhibition of these proteins in tumor samples retrieved from mice bearing H460 tumors treated with MIA690 ( Fig. 6b and Supporting Information, Table S1 ).
In vitro treatment with GHRH antagonists remarkably reduced cAMP levels in the three lung cancer cells (Fig. 6c) . In HCC827 cells, the levels of cellular cAMP were reduced by 40.0% and 43.5%, respectively, upon treatment with MIA690 and MIA602 for 1 hr. In H460 cells, the reduction was 70.8% and 78.0%, and in H446 cells, 43.4% and 51.4%, respectively. The activated CREB (p-CREB/CREB) was significantly reduced by exposure in vitro to 2 lM MIA602 or MIA690 in all three cell lines (Fig. 6d) .
Discussion
MIA602 and MIA690 belong to the latest MIAMI series of potent GHRH antagonists with high antitumor activity on various cancers. 15, 16, [29] [30] [31] [32] In this study, we evaluated systematically the inhibitory effects of MIA602 and MIA690 on both SCLC and NSCLC in vitro and in vivo. The antagonists MIA602 and MIA690 were essentially equipotent on inhibition of growth of these cancers. The selection of cell lines was partially based on the information provided by a report from the Welcome Trust Sanger Institutes in Cambridge, UK. In tests with 975 cancer cell lines, lung cancer cell lines HCC827, H446 and DMS53 were among the ten cancer cell lines with lowest IC50 value in response to MIA 602 (data not shown).
In vitro treatment of SCLC cell lines (H446, DMS53 and H69) and NSCLC cell lines HCC827 and H460 with MIA602 and MIA690 significantly inhibited cell viability and increased cell apoptosis. Both antagonists exerted a remarkable inhibitory effect on DMS53 cells in vitro. However, DMS53 cells grew very slowly in vivo and, it was difficult to establish xenografted cancer model of this line in nude mice. Major tumor suppression was achieved in nude mice xenografted with HCC827, H460 and H446 cancer cells by the administration of these antagonists s.c. at a dose of 5 lg/day. This dose is 2-to 8-fold lower than doses used in our previous studies with JV-I or MZJ series of GHRH antagonists. 20, 23, 24, 27 Our results also clearly show that the exposure in vitro to MIA602 and MIA690 significantly downregulates both pGHRH and SV1 receptors in NSCLC and SCLC cells. A similar downregulation of receptors occurs in xenografted tumors retrieved from nude mice treated in vivo with these antagonists. The results underline the importance of GHRHR in the progression of these lung cancers and the potential utility of GHRH antagonists for the treatment of these lung cancers. Dysregulated cell division, which results in aberrant cell proliferation, is one of the key hallmarks of cancer. To block cell division by targeting of regulatory proteins in the cell cycle is one of potential approaches in the development of anticancer drugs. 33 GHRH antagonists have been reported to induce cell cycle arrest mediated by p21 in colon cancer. 34 In this study, we analyzed for the first time the effects of GHRH antagonists on the expression of key proteins in the cell cycle G1/S transition check point. Cyclin D1/2 and CDKs contribute to the regulation of cancer growth and malignancy because of their central roles in cell cycle progression and control of G1/S checkpoint. Overexpression of cyclin D and the cyclin-dependent kinases CDK4/6 was reported to lead to uncontrolled proliferation of cancers including lung cancers. 35, 36 Overexpression of cyclin D is also considered as a consequence of oncogenic activation of mitogenic signaling pathways including RAS-MEK-ERK and PI3K/AKT pathways. 37, 38 Both cyclin D and CDK4/6 are therapeutic targets in cancer treatment. 33, 37, 38 Our results reveal that GHRH antagonists modulate the expression of these proteins. We demonstrated a significant downregulation of cyclin D1 and D2, and CDK4/6 and a major upregulation of the expression of p27 kip1 , the inhibitor of cyclin- dependent kinase, in the three lung cancer cells exposed in vitro to GHRH antagonists and also in the tumor tissues of animals treated with these analogs (Fig. 5) . The results suggest that GHRH antagonists inhibit lung cell proliferation by blocking the G1 to S transition in the cell cycle. The changes of the expression of these proteins in vitro were more significant than those in tumor samples retrieved from animals treated in vivo, probably due to the heterogeneous nature of tumor tissues. E-cadherin, an epithelial cadherin is a growth and invasion suppressor of cancer cells, which inhibits cell proliferation by upregulation of p27 kip1 . 35, [39] [40] [41] The E-cadherin-catenin complex is critical for intercellular adhesiveness and maintenance of normal and malignant tissue architecture. 39, 42 The loss of E-cadherin in cancer cells is required for the epithelial-mesenchymal transition (EMT) to occur and to promote metastasis. 43 In this study, we demonstrated an enhanced expression of E-cadherin and b-catenin in NSCLC and SCLC cells in vitro and in the tumor tissues after treatment with MIA602 and MIA690. These findings suggest that the treatment with GHRH antagonists could lead to less invasive lung cancers.
Signaling pathways including Raf/Mek/ERK1/2, PI3K/AKT and AMPK metabolic pathway in NSCLCs 22, 23, 26 ; EGF/HER and PKC 21, 27 pathways in SCLCs were found to be associated with the inhibitory effects of GHRH antagonists on lung tumors. This study extends our knowledge of the possible cross talk between the binding of GHRH antagonists to its receptor and other, not yet explored cell signaling pathways in lung cancers. PAK1, a member of the p21-activated kinase family, has been shown to be expressed in a variety of normal tissues, and its expression is significantly increased in several cancers, including lung cancer. 44, 45 It has been reported that the overexpression of PAK1 significantly rescued MIA602 induced antineoplastic effects and enhanced pSTAT3 in gastric cancer cells. 15 Much evidence indicates that PAKs are associated with cell proliferation, resistance to cell apoptosis and activation of invasion and angiogenesis. 44, 46 Meanwhile, STAT3 is the potential effector for G protein-coupled receptors in regulation of cell cycle progression and G protein expression. [47] [48] [49] Our study reveals that GHRH antagonists MIA602 and MIA690 modulate PAK1 expression and STAT3 at protein levels in lung cancers. In addition, these antagonists are also involved in re-modulating of cAMP-CREB pathway in SCLC and NSCLC cells. All these findings suggest that the binding of GHRH antagonists to the GHRH-Rs triggers the cascade of multiple signaling pathways in both NSCLC and SCLC. In a recent study by our group, 50 the stimulatory action of TGF-b2 in prostatic epithelial cells isolated from induced benign hyperplasia of rats was diminished by stable transfection of shRNA constructs that target the expression of pGHRH-R and its SV1. The finding suggests that downregulation of GHRH signaling counteracts the proliferative effects of TGF-b2. Further studies to knockdown the expression of GHRH receptor in lung cancer cells are needed to elucidate the links between GHRH-GHRHR signaling and other signaling pathways.
In summary, this study demonstrates the efficacy of GHRH antagonists, MIA602 and MIA690, in inhibiting the growth of lung cancers in vitro and in vivo and in downregulating of GHRH receptors, which might be associated with cell cycle and multiple signaling pathways in lung cancer. In a collaborative study, we have shown that the expression of GHRH-R is significantly associated with tumor progression and clinical outcome of gastric cancer patients. 15 Clinical studies should be conducted in lung cancer patients to confirm if GHRH-R could be a therapeutic target. Our work supports the potential use of GHRH antagonists for therapy of lung cancers. Our findings suggest the merit of further investigations with GHRH antagonists in the management of both SCLC and NSCLC.
